Jim Simons Pliant Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 101,200 shares of PLRX stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,200

Previous 253,369 60.06%

Holding current value

$1.35 Million

Previous $2.72 Million 58.35%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$10.52 - $14.35 $1.6 Million - $2.18 Million	-152,169 Reduced 60.06%	101,200 $1.13 Million
Q2 2024 Aug 09, 2024	BUY	$10.58 - $15.61 $1.88 Million - $2.77 Million	177,469 Added 233.82%	253,369 $2.72 Million
Q1 2024 May 13, 2024	BUY	$14.14 - $19.59 $1.07 Million - $1.49 Million	75,900 New	75,900 $1.13 Million
Q1 2023 May 12, 2023	BUY	$18.73 - $36.26 $2.2 Million - $4.26 Million	117,400 Added 564.42%	138,200 $3.68 Million
Q4 2022 Feb 13, 2023	SELL	$17.0 - $25.43 $1.25 Million - $1.87 Million	-73,500 Reduced 77.94%	20,800 $402,000
Q3 2022 Nov 14, 2022	SELL	$7.67 - $24.23 $82,836 - $261,684	-10,800 Reduced 10.28%	94,300 $1.97 Million
Q2 2022 Aug 12, 2022	SELL	$4.11 - $8.75 $2,055 - $4,375	-500 Reduced 0.47%	105,100 $842,000
Q1 2022 May 13, 2022	BUY	$7.01 - $14.1 $527,803 - $1.06 Million	75,293 Added 248.43%	105,600 $740,000
Q4 2021 Feb 11, 2022	BUY	$12.27 - $18.26 $3,766 - $5,605	307 Added 1.02%	30,307 $409,000
Q3 2021 Nov 12, 2021	BUY	$16.48 - $28.98 $494,400 - $869,400	30,000 New	30,000 $506,000

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $647M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account